Association of lipoproteins with cytokines and cytokine receptors in heart failure patients. Differences between ischaemic versus idiopathic cardiomyopathy

European Heart Journal

Volumn 24, Issue 24, 2003, Pages 2221-2226

  Conraads, Viviane M ^a   Bosmans, Johan M ^a   Schuerwegh, Annemie J ^a   De Clerck, Luc S ^a   Bridts, Chris H ^a   Wuyts, Floris L ^a   Stevens, Wim J ^a   Vrints, Christiaan J ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cytokines; Heart failure; Inflammation; Lipoproteins

Indexed keywords

CHOLESTEROL; CYTOKINE; CYTOKINE RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HEART FAILURE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, HDL; CORONARY ARTERIOSCLEROSIS; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INTERLEUKIN-6; LIPOPROTEINS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0348219291     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.09.023     Document Type: Article

References (28)

1. Rauchhaus M, Koloczek V, Volk H et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 2000;76:125-33.
2. Levine B, Kalman J, Mayer L et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
3. Ferrari R, Bachetti T, Confortini R et al. Tumor necrosis factor soluble receptor in patients with various degrees of congestive heart failure. Circulation 1995;92:1479-86.
4. Torre-Amione G, Kapadia S, Benedict C et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6.
5. Rauchhaus M, Doehner W, Francis DP et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
6. Deswal A, Petersen NJ, Feldman AM et al. Cytokines and cytokine receptors in advanced heart failure. An analysis of the cytokine database from vesnarinone trial (VEST). Circulation 2001;103:2055-9.
7. Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930-3.
8. Parker TS, Levine DM, Chang JCC et al. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995;63:253-8.
9. Netea MG, de Bont N, Demacker PNM et al. Lipoprotein(a) inhibits lipopolysaccharide-induced tumor necrosis factor alpha production by human mononuclear cells. Infect Immun 1998;66:2365-7.
10. Feingold KR, Funk JL, Moser AH et al. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 1995;63:2041-6.
11. Harris HW, Grunveld C, Feingold KR et al. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990;86:696-702.
12. Netea MG, Demacker PN, Kullberg BJ et al. Increased interleukin-1a and interleukin-1b production by macrophages of low density lipoprotein receptor knock-out mice stimulated with lipopolysaccharide is CD11c/CD18-receptor mediated. Immunology 1998;95:466-72.
13. Pajkrt D, Doran JE, Koster F et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxaemia. J Exp Med 1996;184:1601-8.
14. Vredevoe DL, Woo MA, Doering LV et al. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1998;82:323-8.
15. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
16. Ferro D, Parrotto S, Basili S et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-31.
17. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999;353:983-4.
18. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol 2000;410:83-92.
19. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8.
20. Stenestrand U, Wallentin L. for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-6.
21. Aronow HD, Topol EJ, Roe MT et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001;357:1063-8.
22. Pahan K, Sheikh FG, Namboodiri AMS et al. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997;100:2671-9.
23. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho GTPase. J Biol Chem 1998;273:24266-71.
24. Guijarro C, Blanco-Colio LM, Ortega M et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500.
25. Romano M, Diomede L, Sironi M et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000;80:1095-100.
26. Sakai M, Kobori S, Matsumura T et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997;133:51-9.
27. Dunzendorfer S, Rothbucher D, Schratzberger P et al. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 1997;81:963-9.
28. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1567-73.